Q-omics provides the consensus-scored RPLP0P11 profile across patient tissues and cancer cell-line models. RPLP0P11 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RPLP0P11 is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, RPLP0P11 RNA expression shows 4,585 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight BRCA, LUSC, and UCEC as cancer lineages where RPLP0P11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPLP0P11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPLP0P11 survival associations across molecular data types. RPLP0P11 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPLP0P11 RNA expression–survival associations across cancer types. High RPLP0P11 expression shows unfavorable associations in OV, MESO, LIHC and CHOL, but favorable associations in BRCA and TGCT. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BRCA as the clearest survival context for RPLP0P11 RNA expression.
This table summarizes RPLP0P11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPLP0P11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPLP0P11 shows higher tumor expression in LUSC, HNSC, LIHC, PRAD, COAD and THCA. The LUSC box plot shows higher RPLP0P11 RNA expression in tumor versus normal tissue (log2 FC = +0.044, t-test p = .005).
This table shows molecular features associated with RPLP0P11 in patient tissues and cancer cell lines. In patient samples, RPLP0P11 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
